Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer In Vitro Suppression of Amyloid Fibril Formation

Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics

Volumn , Issue , 2007, Pages 203-218

  Podoly, Erez ^a   Diamant, Sophia ^a   Friedler, Assaf ^a   Livnah, Oded ^a   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 57649142901     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420046625-15     Document Type: Chapter

References (74)

1. Aiuti, A., Ficara, F., Cattaneo, F., Bordignon, C. and Roncarolo, M.G. (2003) Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol, 3, 461-6.
2. Adams, P.D., Arkin, I.T., Engelman, D.M. and Brunger, A.T. (1995) Computational searching and mutagenesis suggest a structure for the pentameric transmembrane domain of phospholamban. Nat Struct Biol, 2, 154-62.
3. Altamirano, C.V. and Lockridge, O. (1999) Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem Biol Interact, 119-120, 53-60.
4. Alvarez, A., Alarcon, R., Opazo, C., Campos, E.O., Mujnoz, F.J., Calderon, F.H., Dajas, F., Gentry, M.K., Doctor, B.P., De Mello, F.G. and Inestrosa, N.C. (1998) Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J Neurosci, 18, 3213-23.
5. Arndt, U., Kaltwasser, J.P., Gottschalk, R., Hoelzer, D. and Moller, B. (2005) Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol, 84, 159-66.
6. Ashani, Y., Shapira, S., Levy, D., Wolfe, A.D., Doctor, B.P. and Raveh, L. (1991) Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol, 41, 37-41.
7. Ballabh, P., Braun, A. and Nedergaard, M. (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis, 16, 1-13.
8. Ballard, C.G., Greig, N.H., Guillozet-Bongaarts, A.L., Enz, A. and Darvesh, S. (2005) Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res, 2, 307-18.
9. Bemporad, F., Taddei, N., Stefani, M. and Chiti, F. (2006) Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. Protein Sci, 15, 862-70.
10. Bryk, B., BenMoyal-Segal, L., Podoly, E., Livnah, O., Eisenkraft, A., Luria, S., Cohen, A., Yehezkelli, Y., Houritz, A. and Soreq, H. (2005) Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J Neurochem, 92, 1216-27.
11. Carson, K.A., Geula, C. and Mesulam, M.M. (1991) Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue. Brain Res, 540, 204-8.
12. Cerasoli, D.M., Griffiths, E.M., Doctor, B.P., Saxena, A., Fedorko, J.M., Greig, N.H., Yu, Q.S., Huang, Y., Wilgus, H., Karatzas, C.N., Koplovitz, I. and Lenz, D.E. (2005) In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact, 157-158, 363-5.
13. Chambers, H.W., Boone, J.S., Carr, R.L. and Chambers, J.E. (2001) Chemistry of Organophosphorus Insecticides, San Diego, Academic Press.
14. Chatonnet, A. and Lockridge, O. (1989) Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J, 260, 625-34.
15. Chromy, B.A., Nowak, R.J., Lambert, M.P., Viola, K.L., Chang, L., Velasco, P.T., Jones, B.W., Fernandez, S.J., Lacor, P.N., Horowitz, P., Finch, C.E., Krafft, G.A. and Klein, W.L. (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry, 42, 12749-60.
16. Citron, M., Diehl, T.S., Gordon, G., Biere, A.L., Seubert, P. and Selkoe, D.J. (1996) Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A, 93, 13170-5.
17. Cruz, L., Urbanc, B., Buldyrev, S.V., Christie, R., Gomez-Isla, T., Havlin, S., McNamara, M., Stanley, H.E. and Hyman, B.T. (1997) Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc Natl Acad Sci U S A, 94, 7612-6.
18. Darvesh, S. and Hopkins, D.A. (2003) Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol, 463, 25-43.
19. Darvesh, S., Hopkins, D.A. and Geula, C. (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci, 4, 131-8.
20. De Rosa, R., Garcia, A.A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N. and Cattaneo, A. (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A, 102, 3811-6.
21. Diamant, S., Podoly, E., Friedler, A., Ligumsky, H., Livnah, O. and Soreq, H. (2006) Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A, 0602922103.
22. Dickson, D.W. (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol, 56, 321-39.
23. Doctor, B.P. and Saxena, A. (2005) Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact, 157-158, 167-71.
24. Dvir, H., Harel, M., Bon, S., Liu, W.Q., Vidal, M., Garbay, C., Sussman, J.L., Massoulie, J. and Silman, I. (2004) The synaptic acetylcholinesterase tetramer assembles around a polyproline II helix. Embo J, 23, 4394-405.
25. Fernandez, H.L., Moreno, R.D. and Inestrosa, N.C. (1996) Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. J Neurochem, 66, 1335-46.
26. Forloni, G., Tagliavini, F., Bugiani, O. and Salmona, M. (1996) Amyloid in Alzheimer’s disease and prionrelated encephalopathies: studies with synthetic peptides. Prog Neurobiol, 49, 287-315.
27. Gallo, M. and Lawryk, N. (1991) Organic Phosphorus Pesticides, San Diego, Academic Press, Inc.
28. Gazit, E. (2002) A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J, 16, 77-83.
29. Giacobini, E. (2003) Cholinergic function and Alzheimer’s disease. Int J Geriatr Psychiatry, 18, S1-5.
30. Giacobini, E. (2004) Cholinesterase inhibitors:newroles and therapeutic alternatives. Pharmacol Res, 50, 433-40.
31. Glick, D., Ben Moyal, L. and Soreq, H. (2003) Genetic Variation in Butyrylcholinesterase and the Physiological Consequences for Acetylcholinesterase Function, London, Martin Dunitz.
32. Greig, N.H., Lahiri, D.K. and Sambamurti, K. (2002) Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy. Int Psychogeriatr, 14 Suppl 1, 77-91.
33. Grunwald, J., Marcus, D., Papier, Y., Raveh, L., Pittel, Z. and Ashani, Y. (1997) Large-scale purification and long-term stability of human butyrylcholinesterase: a potential bioscavenger drug. J Biochem Biophys Methods, 34, 123-35.
34. Guillozet, A.L., Smiley, J.F., Mash, D.C. and Mesulam, M.M. (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol, 42, 909-18.
35. Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 297, 353-6.
36. Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B. and Selkoe, D.J. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci, 19, 8876-84.
37. Head, E. and Lott, I.T. (2004) Down syndrome and beta-amyloid deposition. Curr Opin Neurol, 17, 95-100.
38. Inestrosa, N.C., Alvarez, A. and Calderon, F. (1996a) Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer’s filaments. Mol Psychiatry, 1, 359-61.
39. Inestrosa, N.C., Alvarez, A., Perez, C.A., Moreno, R.D., Vicente, M., Linker, C., Casanueva, O.I., Soto, C. and Garrido, J. (1996b) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron, 16, 881-91.
40. Inestrosa, N.C., Sagal, J.P. and Colombres, M. (2005) Acetylcholinesterase interaction with Alzheimer amyloid beta. Subcell Biochem, 38, 299-317.
41. Jarrett, J.T. and Lansbury, P.T., Jr. (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell, 73, 1055-8.
42. Jbilo, O., Bartels, C.F., Chatonnet, A., Toutant, J.P. and Lockridge, O. (1994) Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon, 32, 1445-57.
43. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W. and Glabe, C.G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-9.
44. Kuo, Y.M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J. and Roher, A.E. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem, 271, 4077-81.
45. La Du, B.N. and Lockridge, O. (1986) Molecular biology of human serum cholinesterase. Fed Proc, 45, 2965-9.
46. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M. and Ashe, K.H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440, 352-7.
47. Levine III, H. (1993) Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci, 2, 404-10.
48. Levine III, H. (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol, 309, 274-84.
49. Levine III, H. (2003) Y10W beta(1-40) fluorescence reflects epitope exposure in conformers of Alzheimer’s beta-peptide. Arch Biochem Biophys, 417, 112-22.
50. Lomakin, A., Chung, D.S., Benedek, G.B., Kirschner, D.A. and Teplow, D.B. (1996) On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci U S A, 93, 1125-9.
51. Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E. and Rogers, J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol, 155, 853-62.
52. McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I. and Masters, C.L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol, 46, 860-6.
53. Meshorer, E., Biton, I.E., Ben-Shaul, Y., Ben-Ari, S., Assaf, Y., Soreq, H. and Cohen, Y. (2005) Chronic cholinergic imbalances promote brain diffusion and transport abnormalities. FASEB J, 19, 910-22.
54. Petkova, A.T., Ishii, Y., Balbach, J.J., Antzutkin, O.N., Leapman, R.D., Delaglio, F. and Tycko, R. (2002) A structural model for Alzheimer’s beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A, 99, 16742-7.
55. Pike, C.J., Walencewicz, A.J., Glabe, C.G. and Cotman, C.W. (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res, 563, 311-4.
56. Porat, Y., Kolusheva, S., Jelinek, R. and Gazit, E. (2003) The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry, 42, 10971-7.
57. Porat, Y., Mazor, Y., Efrat, S. and Gazit, E. (2004) Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry, 43, 14454-62.
58. Raveh, L., Grunwald, J., Marcus, D., Papier, Y., Cohen, E. and Ashani, Y. (1993) Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol, 45, 2465-74.
59. Raveh, L., Grauer, E., Grunwald, J., Cohen, E. and Ashani, Y. (1997) The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol, 145, 43-53.
60. Rees, T., Hammond, P.I., Soreq, H., Younkin, S. and Brimijoin, S. (2003) Acetylcholinesterase promotes betaamyloid plaques in cerebral cortex. Neurobiol Aging, 24, 777-87.
61. Rees, T.M., Berson, A., Sklan, E.H., Younkin, L., Younkin, S., Brimijoin, S. and Soreq, H. (2005) Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res, 2, 291-300.
62. Schwarz, M., Glick, D., Loewenstein, Y. and Soreq, H. (1995) Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol Ther, 67, 283-322.
63. Shaked, I. and Soreq, H. (2006) Studying Cholinergic Features by Transgenic Manipulations of AChE Gene Expression, London, Informa Healthcare.
64. Sklan, E.H., Lowenthal, A., Korner, M., Ritov, Y., Landers, D.M., Rankinen, T., Bouchard, C., Leon, A.S., Rice, T., Rao, D.C., Wilmore, J.H., Skinner, J.S. and Soreq, H. (2004) Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci U S A, 101, 5512-7.
65. Soreghan, B., Kosmoski, J. and Glabe, C. (1994) Surfactant properties of Alzheimer’s A beta peptides and the mechanism of amyloid aggregation. J Biol Chem, 269, 28551-4.
66. Soreq, H. and Zakut, H. (1990) Expression and in vivo amplification of the human acetylcholinesterase and butyrylcholinesterase genes. Prog Brain Res, 84, 51-61.
67. Soreq, H. and Zakut, H. (1993) Human Cholinesterases and Anticholinesterases, San Diego, Academic Press.
68. Standridge, J.B. (2006) Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer’s disease. Curr Alzheimer Res, 3, 95-108.
69. Sun, H., Pang, Y.P., Lockridge, O. and Brimijoin, S. (2002) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol, 62, 220-4.
70. Talesa, V.N. (2001) Acetylcholinesterase in Alzheimer’s disease. Mec Ageing Dev, 122, 1961-9.
71. Tjernberg, L.O., Pramanik, A., Bjorling, S., Thyberg, P., Thyberg, J., Nordstedt, C., Berndt, K.D., Terenius, L. and Rigler, R. (1999) Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy. Chem Biol, 6, 53-62.
72. Wang, S.S., Chen, Y.T. and Chou, S.W. (2005) Inhibition of amyloid fibril formation of beta-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta, 1741, 307-13.
73. Wright, C.I., Geula, C. and Mesulam, M.M. (1993) Neurological cholinesterases in the normal brain and in Alzheimer’s disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol, 34, 373-84.
74. Zhang, J.G., Dan, Q., Fong, T.C., Williams, C.C., Avina, M.D., Tarbiyat-Boldaji, M., Khalaghizadeh, S., Irwin, M., Nguyen, A., Zhuang, J.L., Hoa, N., Wepsic, H.T. and Jadus, M.R. (2005) Macrophage colonystimulating factor expression in retrovirally transduced cells is dependent upon both the adherence status of the target cells and its 50 flanking untranslated region. Biochem Biophys Res Commun, 330, 1275-84.